Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

MLA

Verstovsek, Srdan, et al. “Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized Controlled Trials.” Blood Advances, vol. 7, no. 14, July 2023, pp. 3582–91. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022009311.

APA

Verstovsek, S., Mesa, R., Gupta, V., Lavie, D., Dubruille, V., Cambier, N., Platzbecker, U., Hus, M., Xicoy, B., Oh, S. T., Kiladjian, J.-J., Vannucchi, A. M., Gerds, A., Egyed, M., Mayer, J., Sacha, T., Kawashima, J., Morris, M., Huang, M., & Harrison, C. (2023). Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Advances, 7(14), 3582–3591. https://doi.org/10.1182/bloodadvances.2022009311

Chicago

Verstovsek, Srdan, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, et al. 2023. “Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized Controlled Trials.” Blood Advances 7 (14): 3582–91. doi:10.1182/bloodadvances.2022009311.